The Italian Competition Authority Fines a Pharmaceutical Company for Having 
"Artificially Differentiated" Their Medicinal Products in Breach of Article 101 
TFEU (Roche- Novartis/Farmaci Avastin e Lucentis)

Lembo, Sara; Matarazzi, Giulio

Item

ITEM ACTIONSEXPORT

Add to Basket

Local TagsRelease HistoryDetailsSummary

Released

Journal Article

The Italian Competition Authority Fines a Pharmaceutical Company for Having "Artificially Differentiated" Their Medicinal Products in Breach of Article 101 TFEU (Roche- Novartis/Farmaci Avastin e Lucentis)

MPS-Authors

There are no MPG-Authors in the publication available

External Resource

https://www.concurrences.com/en/bulletin/news-issues/february-2014-en/The-Italian-Competition-Authority-68802
(Preprint)

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

Fulltext (public)

There are no public fulltexts stored in PuRe

Supplementary Material (public)

There is no public supplementary material available

Citation

Lembo, S., & Matarazzi, G. (2014). The Italian Competition Authority Fines a Pharmaceutical Company for Having "Artificially Differentiated" Their Medicinal Products in Breach of Article 101 TFEU (Roche- Novartis/Farmaci Avastin e Lucentis). Bulletin e-Competitions, 68802.

Cite as: https://hdl.handle.net/21.11116/0000-000A-15C1-4

Abstract

There is no abstract available